Clever Leaves Holdings (CLVR)
OTHER OTC:CLVR
Top Page
No summary available
Positive Factors
Improved Gross Profit Margins
The improvement in gross profit margins indicates better cost management, which can enhance long-term profitability and competitiveness.
Negative Factors
Persistent Net Losses
Ongoing net losses and cash flow issues can hinder long-term sustainability and limit the ability to reinvest in business growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Profit Margins
The improvement in gross profit margins indicates better cost management, which can enhance long-term profitability and competitiveness.
Read all positive factors
Clever Leaves Holdings (CLVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05K
Dividend YieldN/A
Average Volume (3M)666.00
Price to Earnings (P/E)―
Beta (1Y)131413.48
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees296
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,754,795
10 Day Avg. Volume216
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.14
Price to Sales (P/S)0.19
P/FCF Ratio-0.28
Enterprise Value/Market Cap-4.50K
Enterprise Value/Revenue-0.27
Enterprise Value/Gross Profit-0.72
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Clever Leaves Holdings Business Overview & Revenue Model
Company Description
Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribut...
How the Company Makes Money
Clever Leaves Holdings generates revenue through its diversified business model, which includes the sale of cannabis extracts, such as CBD and THC oils, as well as dried flower and finished goods to pharmaceutical companies, consumer brands, and o...
Clever Leaves Holdings Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.42M | 16.41M | 15.37M | 12.12M | 7.83M |
| Gross Profit | 6.56M | 4.33M | 6.81M | 7.41M | 3.10M |
| EBITDA | -16.84M | -37.75M | -34.35M | -17.85M | -41.72M |
| Net Income | -17.90M | -66.10M | -45.63M | -36.11M | -45.98M |
Balance Sheet | |||||
| Total Assets | 31.24M | 52.10M | 116.16M | 165.88M | 95.72M |
| Cash, Cash Equivalents and Short-Term Investments | 6.83M | 12.45M | 37.23M | 79.46M | 12.04M |
| Total Debt | 2.09M | 3.86M | 25.09M | 33.84M | 33.73M |
| Total Liabilities | 7.03M | 11.69M | 43.39M | 51.57M | 45.52M |
| Stockholders Equity | 24.22M | 40.41M | 72.77M | 95.25M | 45.50M |
Cash Flow | |||||
| Free Cash Flow | -11.54M | -30.37M | -43.51M | -25.63M | -55.73M |
| Operating Cash Flow | -11.51M | -29.07M | -36.23M | -21.96M | -37.05M |
| Investing Cash Flow | 4.69M | 1.19M | -7.28M | -3.67M | -33.90M |
| Financing Cash Flow | 656.00K | 3.29M | 1.83M | 91.84M | 62.83M |
Clever Leaves Holdings Risk Analysis
Clever Leaves Holdings disclosed 49 risk factors in its most recent earnings report. Clever Leaves Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We effected a one-for-thirty reverse share split of our common shares (the "Reverse Share Split"), in August 2023.The Reverse Share Split may adversely impact the liquidity of our common shares and warrants and may not be effective in facilitating our efforts to maintain compliance with the continued listing requirements of Nasdaq. Q4, 2023
2.
We may choose to delist our securities from Nasdaq and deregister under the Exchange Act, which could negatively affect the liquidity and trading prices of our common shares would result in substantially less disclosure about us and severely impair our ability to raise capital. Q4, 2023
3.
We may not be able to obtain import permits in the destination countries or export permits in Colombia in a timely manner or of the required quantities Q4, 2023
Clever Leaves Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.05K | ― | -73.91% | ― | ― | ― | |
59 Neutral | $352.51M | -37.26 | -1.44% | ― | 1.76% | 18.31% | |
44 Neutral | $786.70M | -8.34 | -92.82% | ― | 2.31% | -726.28% | |
40 Underperform | $2.12M | -0.71 | -93.87% | ― | -0.74% | 81.49% |
* Healthcare Sector Average
CLVR
Clever Leaves Holdings
0.02
0.00
0.00%
TLRY
Tilray
6.75
1.70
33.56%
SNDL
SNDL
1.36
-0.01
-0.73%
IMCC
IM Cannabis Corp
0.34
-0.98
-74.17%
AKAN
Akanda Corp
0.69
-16.03
-95.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―